The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

Shadia I. Jalal, Foluso O. Ademuyiwa, Nasser H. Hanna

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Purpose of review Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40% and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice. Recent findings Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC. Summary Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalCurrent Opinion in Oncology
Volume21
Issue number2
DOIs
StatePublished - Mar 1 2009

Keywords

  • Lung cancer
  • Maintenance/consolidation chemotherapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'The role of maintenance chemotherapy in advanced nonsmall cell lung cancer'. Together they form a unique fingerprint.

Cite this